Publication: Efficacy and safety of switching from low-dose statin to high-intensity statin for primary prevention in type 2 diabetes: A randomized controlled trial
Issued Date
2020-01-01
Resource Type
ISSN
11787007
Other identifier(s)
2-s2.0-85079879800
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol.13, (2020), 423-431
Suggested Citation
Nuntakorn Thongtang, Jirasak Piyapromdee, Natthakan Tangkittikasem, Kittichai Samaithongcharoen, Nithiwat Srikanchanawat, Sutin Sriussadaporn Efficacy and safety of switching from low-dose statin to high-intensity statin for primary prevention in type 2 diabetes: A randomized controlled trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol.13, (2020), 423-431. doi:10.2147/DMSO.S219496 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/53828
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Efficacy and safety of switching from low-dose statin to high-intensity statin for primary prevention in type 2 diabetes: A randomized controlled trial
Other Contributor(s)
Abstract
© 2020 Thongtang et al. Introduction: Statin intensification is required in patients who have high-risk for cardiovascular events. However, it is unclear if this is needed in whom plasma LDL-C target was achieved with low-dose statin for primary prevention. We investigated the efficacy and safety of switching from low-dose statin to high-intensity statin among type 2 diabetes (T2D) who had achieved plasma LDL-C <100 mg/dl with low-dose statin treatment. Methods: T2D patients with no atherosclerotic cardiovascular disease who had plasma LDL-C level <100 mg/dl while taking simvastatin ≤20 mg/day were randomized to continue using the same dosage of simvastatin (low-dose statin group; LS) for 12 weeks, or to switch to atorvastatin 40 mg/ day for 6 weeks, and then, if tolerated, to atorvastatin 80 mg/day for 6 weeks (high-intensity statin group; HS). Biochemical test and adverse events were evaluated at baseline, 6 weeks, and 12 weeks. Results: One hundred and fifty patients (76 LS, 74 HS, mean age 58.9±8.9 years, 72% female) were included. The mean baseline plasma LDL-C level on statin was slightly higher in the HS group (71.9±13.6 vs. 68.1±14.2 mg/dl, p=0.09). The HS group had a significantly lower plasma LDL-C level at both 6 and 12 weeks (both p<0.001). Plasma LDL-C <40 mg/dl was found more frequently in the HS group (23.0% vs. 3.9%, p<0.001). Discontinuation of statin due to adverse effects was more frequent in the HS group (5.4% vs. 1.3%, p=0.38 for atorvastatin 40 mg/day, 12.2% vs. 1.3%, p=0.03 for atorvastatin 80 mg/day). No serious adverse events were observed in either group. Conclusion: Switching from low-dose statins to high-intensity statins resulted in a significant reduction in plasma LDL-C levels, and was fairly well tolerated during a 12-week study period.